(07 Sep 2020) LMW Heparin- D-dimer, and CRP levels were significantly improved in the LMWH group

The impact of the “low molecular weight heparin” administration on the clinical course of COVID-19 disease

https://doi.org/10.3906/sag-2006-184

This study aimed to investigate the clinical impact of a low molecular weight heparin (LMWH) treatment on the clinical course of COVID-19. Participants were separated into two groups: one was treated with LMWH and the other was not.  Ninety-six patients who were diagnosed with COVID-19 between April and May 2020 were retrospectively analyzed. The multivariable analysis showed that the count of lymphocytes, D-dimer, and CRP levels were significantly improved in the LMWH group, as compared to the control group (OR, (95% CI) 0.628 (0.248?0.965), p < 0.001), OR, (95% CI) 0.356 (0.089?0.674), p < 0.001, respectively). The area under the receiver operating characteristic (ROC) curve analysis was AUC: 0.679 +/- 0.055, 0.615 +/- 0.058, 0.633 +/- 0.057, respectively, the ss value was found as -1.032, -0.026, and -0.465, respectively. LMWH treatment group demonstrated better laboratory findings, including a recovery in the lymphocyte count, CRP, and D-dimer results.